PressNovember 1, 2022 PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome
PressNovember 1, 2022 Irwin Naturals Looks to Add to Florida Foothold, Expanding Chain of Healthcare Clinics
PressNovember 1, 2022 Apex Labs Granted Approval for North America’s First Take Home Psilocybin Clinical Trial
PressNovember 1, 2022 Numinus Re-Launches “Psychedelic Therapy Frontiers” Podcast with additional hosts and topics
PressOctober 31, 2022 ENOSIS THERAPEUTICS AND OVID CLINICS ANNOUNCE PARTNERSHIP TO LAUNCH WORLD’S FIRST IN-CLINIC APPLICATION OF VIRTUAL REALITY MODULATED PSYCHEDELIC-AUGMENTED PSYCHOTHERAPY
PressOctober 31, 2022 Better U Expanding Psychedelic-Assisted Therapies to 9 States with Immersive Healing Centers
PressOctober 31, 2022 Small Pharma Receives Approval for First-In-Human Phase I Clinical Trial With SPL028
PressOctober 31, 2022 Silo Wellness to Testify on Oregon Psilocybin Therapy Land Use Restrictions at Jackson County Planning Commission’s Thursday Hearing; Other Corporate Updates
PressOctober 31, 2022 Soft Reboot Wellness’ Ketamine Depression Treatment Now Available for Los Altos
PressOctober 30, 2022 Clairvoyant’s Phase 2 Psilocybin Therapy Trial for Alcohol Use Disorder Obtains Regulatory Approval and Initiates 1st Clinical Site in Finland
PressOctober 30, 2022 Love Pharma – Johns Hopkins University Psilocybin Trial Advances Toward Launch in 2022
PressOctober 30, 2022 Mindset Pharma Announces Poster Presentations at Two Upcoming Scientific Conferences
PressOctober 30, 2022 Numinus Launches Psychedelic-Assisted Therapy for Chronic and Serious Medical Illness
PressOctober 29, 2022 COMPASS Pathways plc to announce third quarter 2022 financial results on 3 November 2022
PressOctober 27, 2022 Seelos Therapeutics to Sponsor and Participate in Wonderland, the World’s Leading Psychedelic Event
